featured sponsor Catalent
sponsors
sponsors PhRMA
Takeda
Egnyte
PwC
January 11
MONDAY
8:30 - 9:00am PST
local time

Fireside Chat with Catalent CEO John Chiminski

In a return to our popular event during the last JP Morgan, Endpoints Editor John Carroll will sit down with Catalent CEO John Chiminski to talk about the year ahead, offering their projections for what 2021 holds in store for the biopharma industry. We’re told Chiminski will be wearing his lucky boots.

Catalent
John Chiminski
John Chiminski
Chairman & CEO
Catalent
John Carroll
John Carroll
Editor & Founder
Endpoints News
January 11
MONDAY
9:05 - 10:00am PST
local time

The drug pricing debate is reshaping for a new administration

Under President Trump the industry was offered a series of executive orders designed to bring European and US prices in line, with the promise for price cuts for Americans. Newly elected President Joe Biden has suggested adopting a new approach modeled along Germany’s get-tough negotiations that tie prices to the medical value they offer patients — as determined by government negotiators. So we’re in for a brand new round of discussions in Washington DC that will have a major impact on the fate of biopharma companies. Don’t miss it.

PhRMA
Stephen Ubl
Stephen Ubl
President & CEO
PhRMA
Ellen Sigal
Ellen Sigal
Founder and Chairperson
Friends of Cancer Research
Peter Kolchinsky
Peter Kolchinsky
Managing Partner
RA Capital Management
Peter Bach
Peter Bach
Director, Center for Health Policy and Outcomes
MSKCC
John Carroll
John Carroll
Editor & Founder
Endpoints News
January 12
TUESDAY
8:00 - 9:00am PST
local time

Biopharma dealmaking, 2021 style

During 2020 we saw a burst of new deals as various players began to collaborate on new drugs and vaccines for Covid-19. The mRNA field arrived on the commercial playing field with a bang, promising to reshape the multibillion-dollar vaccine industry. And dealmakers of all shapes and sizes switched over to Zoom and found a new, and often far more efficient, way to do deals at a time money has been pouring into R&D organizations promising to revolutionize treatments for all diseases. That’s the setting, so how will that all play out in the year ahead? Let's talk terms.

PwC
Glenn Hunzinger
Glenn Hunzinger
US Pharmaceutical & Life Sciences Leader
PwC
Elizabeth A. Mily
Elizabeth Mily
EVP, Strategy & Business Development
Bristol Myers Squibb
Deborah Baron
Deborah Baron
Senior Vice President
Worldwide Business Development for Pfizer Inc.
James Sabry
James Sabry
Global Head of Pharma Partnering
Roche
Marianne DeBacker
Marianne DeBacker
EVP and Head of Strategy, Business Development & Licensing
Bayer
John Carroll
John Carroll
Editor & Founder
Endpoints News
January 12
TUESDAY
9:05 - 10:00am PST
local time

Cancer R&D: The second wave takes shape

Following the burst of PD-(L)1 drugs from Merck, Bristol Myers and others, we’re seeing the next big wave of ADCs, cell therapy 2.0, combos and cocktails take shape — possibly even the first truly commoditized checkpoints as well. How is this market going to shape up for the leaders in what has been the fastest growing segment of R&D for the past decade? And how will the pandemic influence the work? We’re calling in the experts.

Takeda
Aviv Regev
Aviv Regev
Head of Research and Early Development
Genentech
James Bradner
James Bradner
President of the Novartis Institutes for BioMedical Research (NIBR)
Novartis
Rupert Vessey
Rupert Vessey
Executive Vice President and President, Research and Early Development
Bristol Myers Squibb
Jose Baselga
Jose Baselga
EVP, Oncology Research & Development
AstraZeneca
Andrew Plump
Andrew Plump
President, Research and Development
Takeda
Dean Li
Dean Li
President
Merck Research Laboratories
Hal Barron
Hal Barron
CSO & President, R&D
GlaxoSmithKline
John Carroll
John Carroll
Editor & Founder
Endpoints News
January 13
WEDNESDAY
9:05 - 10:00am PST
local time

Gene therapy, 2.0

The booming gene therapy field has underscored the opportunities for new treatments, and all the limitations we’ve been seeing over 2020 among the pioneers in the field. What are the key technical issues involved in AAV and lentiviral work, and who’s setting the pace on payload and durability? Will first-to-market status offer big advantages, or limited markets as patients wait for the best-in-market players out there?

Egnyte
Stephen Ubl
Sandy Macrae
President & CEO
Sangamo
Dave Lennon
Dave Lennon
President
Novartis Gene Therapies
James M. Wilson
James Wilson
Professor
University of Pennsylvania
Katherine High
Katherine High
Visiting Professor
Rockefeller University
Sandy Macrae
Sandy Macrae
President and CEO
Sangamo
Alok Tayi
Alok Tayi
VP of Life Sciences
Egnyte
John Carroll
John Carroll
Editor & Founder
Endpoints News